Home Cart Sign in  
Chemical Structure| 143-07-7 Chemical Structure| 143-07-7

Structure of Lauric Acid
CAS No.: 143-07-7

Chemical Structure| 143-07-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lauric acid is a saturated medium-chain fatty acid with a 12-carbon backbone. Lauric acid is found naturally in various plant and animal fats and oils, and is a major component of coconut oil and palm kernel oil.

Synonyms: Dodecanoic acid; Dodecylic acid; GT-08

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lauric Acid

CAS No. :143-07-7
Formula : C12H24O2
M.W : 200.32
SMILES Code : CCCCCCCCCCCC(O)=O
Synonyms :
Dodecanoic acid; Dodecylic acid; GT-08
MDL No. :MFCD00002736
InChI Key :POULHZVOKOAJMA-UHFFFAOYSA-N
Pubchem ID :3893

Safety of Lauric Acid

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H318-H410
Precautionary Statements:P273-P280-P305+P351+P338+P310-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CHL cells 27.40 ± 12.78 μM 50 ms To investigate the inhibitory effect of lauric acid on Na V1.5 channel, results showed that lauric acid dose-dependently inhibited Na V1.5 current. Drug Des Devel Ther. 2025 Jan 9;19:141-157
Mouse primary hepatocytes 0.5 mmol/L 24 hours To investigate the effect of lauric acid on HNF4α and p38 MAPK signaling pathways, results showed that lauric acid stimulation significantly increased the phosphorylation levels of HNF4α and p38 MAPK. EMBO J. 2024 Feb;43(4):507-532
hiPSC-derived cardiomyocytes 1 mM to 100 nM 30 s To evaluate the effect of lauric acid on hiPSC-CMs, results showed that lauric acid reduced EFP amplitude. Drug Des Devel Ther. 2025 Jan 9;19:141-157
Staphylococcus aureus 1024 µg/mL 24 hours To evaluate the antagonistic effect of lauric acid in combination with oxacillin against Staphylococcus aureus. Results showed that lauric acid at 1024 µg/mL in combination with oxacillin exhibited antagonistic action with fractional inhibitory concentration indices (FICI) ranging from 4.01 to 4.28. Sci Rep. 2021 Jan 8;11(1):177
H9c2 rat cardiomyoblasts 40 μg/mL In the in vitro cachexia model, combined treatment with LAA and high glucose restored mitochondrial respiration and glycolysis, ATP to control levels, and reduced oxidative stress Cancer Sci. 2020 Dec;111(12):4605-4615
HT29 colon cancer cells 40 µg/mL 48 hours Lauric acid suppressed HT29 cell proliferation, induced mitochondrial oxidative stress (ROS), inhibited oxidative phosphorylation (OXPHOS), and induced apoptosis. Int J Mol Sci. 2025 Feb 24;26(5):1953
CT26 colon cancer cells 40 µg/mL 48 hours Lauric acid suppressed CT26 cell proliferation, induced mitochondrial oxidative stress (ROS), inhibited oxidative phosphorylation (OXPHOS), and induced apoptosis. Int J Mol Sci. 2025 Feb 24;26(5):1953
CT26 cells 40 µg/mL 48 hours Lauric acid reversed 5FU resistance by inducing OXPHOS, increasing ROS levels, and inducing cell death. Int J Mol Sci. 2025 Jan 14;26(2):664
HT29 cells 40 µg/mL 48 hours Lauric acid reversed 5FU resistance by inducing OXPHOS, increasing ROS levels, and inducing cell death. Int J Mol Sci. 2025 Jan 14;26(2):664

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Drosophila melanogaster Α-synuclein transgenic Parkinson's disease model Dietary administration 250 mg/kg diet 21 days Lauric acid (LA) alone or in combination with levodopa (LD) significantly improved Parkinson's disease-like features in the transgenic Drosophila model by modulating neurobehavioral activities, reducing oxidative stress, and regulating apoptotic and inflammatory processes. Brain Behav. 2024 Sep;14(9):e70001
BALB/c mice Cachexia model Oral 2% (w/w) Free intake LAA alone did not significantly improve myocardial atrophy, but combined administration with glucose restored myocardial atrophy and MYL1 to control levels Cancer Sci. 2020 Dec;111(12):4605-4615
BALB/c mice CT26 peritoneal dissemination model Oral 2% (w/w) diet Daily administration for two weeks Lauric acid significantly reduced tumor weight and ascites volume, increased the number of effector T cells, and enhanced antitumor immune responses. Int J Mol Sci. 2025 Feb 24;26(5):1953
BALB/c mice CT26 mouse cachexia model Oral 2% w/w 15 days The C8 diet showed a greater effect on improving myocardial damage compared with C10 and C12 diets. C8 restored approximately 10% of heart weight and improved cardiomyocyte area and myocardial lipid peroxidation. Int J Mol Sci. 2024 Jul 24;25(15):8081

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01826422 Muscular Dystrophy, Duchenne Not Applicable Completed - Mexico ... More >> Unit of Medical Researcha in Nutrition, Pediatric Hospital, IMSS. Mexico city, Mexico, 06720 Less <<
NCT01826422 - Completed - -
NCT01996566 - Completed - United States, Indiana ... More >> Purdue University West Lafayette, Indiana, United States, 47907 Less <<
NCT02800538 Healthy Volunteers Not Applicable Completed - Belgium ... More >> University Hospitals Leuven, campus Gasthuisberg Leuven, Belgium, 3000 Less <<
NCT00439582 Cardiovascular Disease Not Applicable Completed - France ... More >> Centre de Recherche en Nutrition Humaine (CRNH), UEN, Laboratoire de Nutrition Humaine Clermont-Ferrand, France, 63009 Less <<
NCT02883751 Diabetes Mellitus ... More >> Amputation Stumps Diabetic Foot Less << Not Applicable Unknown December 2018 Brazil ... More >> Universidade Nove de Julho São Paulo, SP, Brazil, 01504015 Less <<
NCT00843466 Hand Dermatosis Not Applicable Completed - United States, North Carolina ... More >> Wake Forest University Health Sciences Dermatology Winston-Salem, North Carolina, United States, 27157 Less <<
NCT02982616 Healthy Volunteers Not Applicable Completed - Belgium ... More >> University Hospitals Leuven, campus Gasthuisberg Leuven, Belgium, 3000 Less <<
NCT00843466 - Completed - -
NCT02809235 Asthma Not Applicable Not yet recruiting July 2018 United States, Massachusetts ... More >> Asthma Research Center, Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Less <<
NCT01962844 Chronic Coronary Artery Diseas... More >>e Less << Not Applicable Unknown March 2014 Brazil ... More >> Instituto Nacional do Coração Rio de Janeiro, Brazil, 22240-002 Less <<
NCT02984150 Healthy Volunteers Not Applicable Completed - Belgium ... More >> University Hospitals Leuven, campus Gasthuisberg Leuven, Belgium, 3000 Less <<
NCT01109381 Helicobacter Pylori Infection Phase 1 Phase 2 Terminated(Poor efficacy (2 of... More >> 31 completing participants with H.pylori eradication)) Less << - Singapore ... More >> Singapore General Hospital Singapore, Singapore Less <<
NCT01109381 - Terminated(Poor efficacy (2 of... More >> 31 completing participants with H.pylori eradication)) Less << - -
NCT03481608 Diet Modification Not Applicable Completed - United States, New York ... More >> Human Metabolic Research Unit, Cornell University Ithaca, New York, United States, 14853 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.99mL

1.00mL

0.50mL

24.96mL

4.99mL

2.50mL

49.92mL

9.98mL

4.99mL

References

 

Historical Records

Categories